Tag: GLP-1 competition

Altcoins

Novo Nordisk Downgrade: Semaglutide Patent Risks in 2026

TD Cowen just downgraded Novo Nordisk to Hold, slashing the price target as semaglutide patent losses loom in key markets....

10/03/2026

4 views

Read More

Market News

Novo Nordisk’s Tough 2026: Obesity Drug Battles Ahead

Novo Nordisk kicked off 2026 with a blockbuster oral obesity pill launch, but lawsuits, disappointing guidance, and fierce competition have...

11/02/2026

4 views

Read More

Market News

Novo’s Wegovy FDA Win Boosts Shares Amid GLP-1 Rivalry

Novo Nordisk's Wegovy just scored a major FDA win for liver disease, boosting shares. Is this the turning point for...

18/08/2025

3 views

Read More